Pregnancy outcome after cabergoline treatment in early weeks of gestation

Elena Ricci, Fabio Parazzini, Tiziano Motta, Carlo I. Ferrari, Annamaria Colao, Antonio Clavenna, Francesca Rocchi, Emanuela Gangi, Sandra Paracchi, Maurizio Gasperi, Maurizio Lavezzari, Anna Elisa Nicolosi, Simona Ferrero, Maria Luisa Landi, Paolo Beck-Peccoz, Maurizio Bonati

Research output: Contribution to journalArticle

Abstract

We collected information on 61 pregnancies in 50 women treated with cabergoline. These pregnancies resulted in 12 (19.7%) early terminations (five induced abortions, six spontaneous abortions, one hydatidiform mole) and 49 (80.3%) live births. In one case, malformations were suspected by a gynecologist based on ultrasound at 12 gestational weeks and the pregnancy was terminated; additional information was not available. There was one case of trisomy 18. The frequency of spontaneous and induced abortions and major congenital malformations was comparable with rates in the general population. The data did not indicate any potential adverse effect of the drug on pregnancy. The data from this study in combination with previous reports can exclude a congenital malformation risk greater than 10% associated with pregnancy exposure to cabergoline.

Original languageEnglish
Pages (from-to)791-793
Number of pages3
JournalReproductive Toxicology
Volume16
Issue number6
DOIs
Publication statusPublished - Nov 2002

Fingerprint

Pregnancy Outcome
Pregnancy
Induced Abortion
Spontaneous Abortion
Ultrasonics
Therapeutics
Hydatidiform Mole
Pharmaceutical Preparations
Live Birth
cabergoline
Population

Keywords

  • Cabergoline
  • Drug adverse effects
  • Newborn
  • Pregnancy

ASJC Scopus subject areas

  • Toxicology

Cite this

Pregnancy outcome after cabergoline treatment in early weeks of gestation. / Ricci, Elena; Parazzini, Fabio; Motta, Tiziano; Ferrari, Carlo I.; Colao, Annamaria; Clavenna, Antonio; Rocchi, Francesca; Gangi, Emanuela; Paracchi, Sandra; Gasperi, Maurizio; Lavezzari, Maurizio; Nicolosi, Anna Elisa; Ferrero, Simona; Landi, Maria Luisa; Beck-Peccoz, Paolo; Bonati, Maurizio.

In: Reproductive Toxicology, Vol. 16, No. 6, 11.2002, p. 791-793.

Research output: Contribution to journalArticle

Ricci, E, Parazzini, F, Motta, T, Ferrari, CI, Colao, A, Clavenna, A, Rocchi, F, Gangi, E, Paracchi, S, Gasperi, M, Lavezzari, M, Nicolosi, AE, Ferrero, S, Landi, ML, Beck-Peccoz, P & Bonati, M 2002, 'Pregnancy outcome after cabergoline treatment in early weeks of gestation', Reproductive Toxicology, vol. 16, no. 6, pp. 791-793. https://doi.org/10.1016/S0890-6238(02)00055-2
Ricci, Elena ; Parazzini, Fabio ; Motta, Tiziano ; Ferrari, Carlo I. ; Colao, Annamaria ; Clavenna, Antonio ; Rocchi, Francesca ; Gangi, Emanuela ; Paracchi, Sandra ; Gasperi, Maurizio ; Lavezzari, Maurizio ; Nicolosi, Anna Elisa ; Ferrero, Simona ; Landi, Maria Luisa ; Beck-Peccoz, Paolo ; Bonati, Maurizio. / Pregnancy outcome after cabergoline treatment in early weeks of gestation. In: Reproductive Toxicology. 2002 ; Vol. 16, No. 6. pp. 791-793.
@article{65f4292b1892469d8699d0e823badab7,
title = "Pregnancy outcome after cabergoline treatment in early weeks of gestation",
abstract = "We collected information on 61 pregnancies in 50 women treated with cabergoline. These pregnancies resulted in 12 (19.7{\%}) early terminations (five induced abortions, six spontaneous abortions, one hydatidiform mole) and 49 (80.3{\%}) live births. In one case, malformations were suspected by a gynecologist based on ultrasound at 12 gestational weeks and the pregnancy was terminated; additional information was not available. There was one case of trisomy 18. The frequency of spontaneous and induced abortions and major congenital malformations was comparable with rates in the general population. The data did not indicate any potential adverse effect of the drug on pregnancy. The data from this study in combination with previous reports can exclude a congenital malformation risk greater than 10{\%} associated with pregnancy exposure to cabergoline.",
keywords = "Cabergoline, Drug adverse effects, Newborn, Pregnancy",
author = "Elena Ricci and Fabio Parazzini and Tiziano Motta and Ferrari, {Carlo I.} and Annamaria Colao and Antonio Clavenna and Francesca Rocchi and Emanuela Gangi and Sandra Paracchi and Maurizio Gasperi and Maurizio Lavezzari and Nicolosi, {Anna Elisa} and Simona Ferrero and Landi, {Maria Luisa} and Paolo Beck-Peccoz and Maurizio Bonati",
year = "2002",
month = "11",
doi = "10.1016/S0890-6238(02)00055-2",
language = "English",
volume = "16",
pages = "791--793",
journal = "Reproductigve Toxicoloy",
issn = "0890-6238",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Pregnancy outcome after cabergoline treatment in early weeks of gestation

AU - Ricci, Elena

AU - Parazzini, Fabio

AU - Motta, Tiziano

AU - Ferrari, Carlo I.

AU - Colao, Annamaria

AU - Clavenna, Antonio

AU - Rocchi, Francesca

AU - Gangi, Emanuela

AU - Paracchi, Sandra

AU - Gasperi, Maurizio

AU - Lavezzari, Maurizio

AU - Nicolosi, Anna Elisa

AU - Ferrero, Simona

AU - Landi, Maria Luisa

AU - Beck-Peccoz, Paolo

AU - Bonati, Maurizio

PY - 2002/11

Y1 - 2002/11

N2 - We collected information on 61 pregnancies in 50 women treated with cabergoline. These pregnancies resulted in 12 (19.7%) early terminations (five induced abortions, six spontaneous abortions, one hydatidiform mole) and 49 (80.3%) live births. In one case, malformations were suspected by a gynecologist based on ultrasound at 12 gestational weeks and the pregnancy was terminated; additional information was not available. There was one case of trisomy 18. The frequency of spontaneous and induced abortions and major congenital malformations was comparable with rates in the general population. The data did not indicate any potential adverse effect of the drug on pregnancy. The data from this study in combination with previous reports can exclude a congenital malformation risk greater than 10% associated with pregnancy exposure to cabergoline.

AB - We collected information on 61 pregnancies in 50 women treated with cabergoline. These pregnancies resulted in 12 (19.7%) early terminations (five induced abortions, six spontaneous abortions, one hydatidiform mole) and 49 (80.3%) live births. In one case, malformations were suspected by a gynecologist based on ultrasound at 12 gestational weeks and the pregnancy was terminated; additional information was not available. There was one case of trisomy 18. The frequency of spontaneous and induced abortions and major congenital malformations was comparable with rates in the general population. The data did not indicate any potential adverse effect of the drug on pregnancy. The data from this study in combination with previous reports can exclude a congenital malformation risk greater than 10% associated with pregnancy exposure to cabergoline.

KW - Cabergoline

KW - Drug adverse effects

KW - Newborn

KW - Pregnancy

UR - http://www.scopus.com/inward/record.url?scp=18644377455&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18644377455&partnerID=8YFLogxK

U2 - 10.1016/S0890-6238(02)00055-2

DO - 10.1016/S0890-6238(02)00055-2

M3 - Article

C2 - 12401507

AN - SCOPUS:18644377455

VL - 16

SP - 791

EP - 793

JO - Reproductigve Toxicoloy

JF - Reproductigve Toxicoloy

SN - 0890-6238

IS - 6

ER -